Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma
The accrual of myeloid-derived suppressor cells (MDSCs) represents a major obstacle to
effective immunotherapy in cancer patients, but the mechanisms underlying this process in the …
effective immunotherapy in cancer patients, but the mechanisms underlying this process in the …
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1
…, E Rankin, G Parmiani, F Arienti… - … journal of cancer, 1999 - Wiley Online Library
Thirty‐nine tumor‐bearing patients with metastatic melanoma were treated with 3 subcutaneous
injections of the MAGE‐3.A1 peptide at monthly intervals. No significant toxicity was …
injections of the MAGE‐3.A1 peptide at monthly intervals. No significant toxicity was …
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings
…, L Pilla, G Tragni, C Lombardo, F Arienti… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: To determine the immunogenicity and antitumor activity of a vaccine consisting
of autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96, …
of autologous, tumor-derived heat shock protein gp96-peptide complexes (HSPPC-96, …
Expression of MAGE genes in primary and metastatic cutaneous melanoma
…, D Liénard, B Lethé, S Carrel, F Arienti… - … journal of cancer, 1995 - Wiley Online Library
Human genes MAGE‐1 and MAGE‐3 code for antigens that are recognized on melanoma
cells by autologous cytolytic T lymphocytes. These antigens may constitute useful targets for …
cells by autologous cytolytic T lymphocytes. These antigens may constitute useful targets for …
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
DJ Hicklin, Z Wang, F Arienti, L Rivoltini… - The Journal of clinical …, 1998 - jci.org
The potential negative impact of HLA class I antigen abnormalities on the outcome of T cell-based
immunotherapy of melanoma has prompted us to investigate the mechanisms …
immunotherapy of melanoma has prompted us to investigate the mechanisms …
Immunization of Stage IV Melanoma Patients with Melan-A/MART-1 and gp100 Peptides plus IFN-α Results in the Activation of Specific CD8+ T Cells and Monocyte …
…, M Santinami, A Cova, G Sovena, F Arienti… - Cancer …, 2006 - aacrjournals.org
The use of IFN-α in clinical oncology has generally been based on the rationale of exploiting
its antiproliferative and antiangiogenic activities. However, IFN-α also exhibits enhancing …
its antiproliferative and antiangiogenic activities. However, IFN-α also exhibits enhancing …
Regression of advanced ovarian carcinoma by Intraperitoneal treatment with autologous TLymphocytes retargeted by a bispecific monoclonal antibody
S Canevari, G Stoter, F Arienti, G Bolis… - JNCI: Journal of the …, 1995 - academic.oup.com
Background: The high frequency of relapse after induction chemotherapy of advanced ovarian
carcinoma calls for new therapeutic approaches. Lysis of ovarian carcinoma cells can be …
carcinoma calls for new therapeutic approaches. Lysis of ovarian carcinoma cells can be …
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic …
…, A Marchianò, C Santantonio, D Tosi, F Arienti… - Cancer Immunology …, 2006 - Springer
The aim of this study was to determine the immunogenicity and antitumor activity of
autologous, tumor-derived heat shock protein gp96-peptide complex vaccine (HSPPC-96; …
autologous, tumor-derived heat shock protein gp96-peptide complex vaccine (HSPPC-96; …
Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b
…, F Perrone, E Tamborini, A Gloghini, F Arienti… - …, 2015 - pmc.ncbi.nlm.nih.gov
In melanoma, the adaptative cell response to BRAF inhibitors includes altered patterns of
cytokine production contributing to tumor progression and drug resistance. Among the factors …
cytokine production contributing to tumor progression and drug resistance. Among the factors …
Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia …
C Gambacorti-Passerini, F Grignani, F Arienti… - 1993 - ashpublications.org
Fusion proteins present in leukemic cells frequently contain a new amino acid at the fusion
point. We tested whether a peptide (BCR1/25) encompassing the fusion region of the hybrid …
point. We tested whether a peptide (BCR1/25) encompassing the fusion region of the hybrid …
